{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:50:09Z","timestamp":1772527809833,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Objectives<\/jats:title>\n          <jats:p>Tumor-induced osteomalacia (TIO), a rare paraneoplastic syndrome, is curable by excision or destruction of the causative tumor. However, occasionally, TIO may relapse after surgical intervention. We aimed to investigate the roles of <jats:sup>18<\/jats:sup>F-FDG PET\/CT in the prognosis of TIOs.<\/jats:p>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventy-six patients who had surgically removed tumors that caused osteomalacia were included in this retrospective investigation. All patients underwent both <jats:sup>18<\/jats:sup>F-FDG and <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT prior to surgery. The prognostic value of presurgical FDG PET\/CT study was determined with 5-year follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the presurgical evaluation, <jats:sup>68<\/jats:sup>Ga-DOTATATE detected lesions in all 76 patients. However, FDG PET\/CT was positive in only 25 among all 76 patients. Following surgical removal of the causative tumor, all 76 patients had symptomatic relief and normalization of the serum phosphate level initially. However, 15 of 76 cases (19.7%) had recurrent hypophosphatemia and became symptomatic again during the follow-up. Among these 15 patients with recurrence, 11 (73.3%) had recurrent lesions at the original location of the resected causative tumors, whereas 4 were in other locations due to malignant nature of the primary tumor. Interestingly, 14 of these 15 patients with recurrent disease had positive presurgical FDG PET\/CT findings with an incident ratio of 56.0% (14 of 25). In contrast, only 1 patient with recurrent disease had negative presurgical FDG PET\/CT scan with an incident ratio of 1.9% (1 of 51), significantly less than the positive presurgical FDG PET\/CT group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A positive presurgical FDG PET\/CT suggests increased likelihood for possible recurrence of TIO after surgical resection. In contrast, when a causative tumor detected by <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT does not have elevated activity on FDG PET\/CT, the chance of recurrence is very small.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003463","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T14:29:03Z","timestamp":1608647343000},"page":"214-219","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic Value of Positive Presurgical FDG PET\/CT in the Evaluation of Tumor-Induced Osteomalacia"],"prefix":"10.1097","volume":"46","author":[{"given":"Peipei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJM199406093302304","article-title":"Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","article-title":"Tumor-induced osteomalacia","volume":"7","year":"2017","journal-title":"Bone Rep"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/PAS.0000000000000890","article-title":"Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum","volume":"41","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"bib4-20250621","article-title":"Tumor-induced osteomalacia","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"bib5-20250621","first-page":"512","article-title":"Tumor-induced osteomalacia: an up-to-date review","volume":"17","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/RLU.0000000000002550","article-title":"Giant cell tumor of tendon sheath revealed on 68Ga-DOTA-TATE PET\/CT in a patient with suspicious tumor-induced osteomalacia","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1097\/RLU.0000000000002076","article-title":"Tumor-induced osteomalacia caused by a parotid basal cell adenoma detected by 68Ga-DOTANOC PET\/CT","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1210\/jc.2014-2120","article-title":"Ovarian cancer-related hypophosphatemic osteomalacia\u2014a case report","volume":"99","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/RLU.0b013e3182a20ded","article-title":"Osteomalacia-inducing renal clear cell carcinoma uncovered by 99mTc-hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) scintigraphy","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/RLU.0000000000002458","article-title":"99mTc-HYNIC-TOC in the evaluation of recurrent tumor-induced osteomalacia","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1007\/s00259-018-3971-x","article-title":"Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET\/CT for detecting osteomalacia-associated tumours","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","first-page":"78","article-title":"68Ga-DOTATATE positron emission tomography\/computed tomography to detect the recurrence of phosphaturic mesenhcymal tumor-induced osteomalacia","volume":"19","year":"2019","journal-title":"World J Nucl Med"},{"key":"bib13-20250621","first-page":"e55","article-title":"PET\/CT localisation of a scapular haemangiopericytoma with tumour-induced osteomalacia","volume":"50","year":"2009","journal-title":"Singapore Med J"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2005.01.001","article-title":"Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET\/CT scan for the diagnosis and follow-up in one case","volume":"36","year":"2005","journal-title":"Bone"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","article-title":"Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in localization of tumor causing oncogenic osteomalacia","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cen.12426","article-title":"Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET\/CT vs somatostatin receptor\u2013based functional scans: a series of nine patients","volume":"81","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/RLU.0000000000000854","article-title":"68Ga DOTATATE PET\/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/RLU.0000000000002290","article-title":"Increased activity due to fractures does not significantly affect the accuracy of 68Ga-DOTATATE PET\/CT in the detection of culprit tumor in the evaluation of tumor-induced osteomalacia","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/RLU.0b013e3182996293","article-title":"99mTc-HYNIC-TOC (99mTc-hydrazinonicotinyl-Tyr3-octreotide) scintigraphy identifying two separate causative tumors in a patient with tumor-induced osteomalacia (TIO)","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/RLU.0b013e318279eb13","article-title":"Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using 68Ga-DOTANOC PET\/CT","volume":"38","year":"2013","journal-title":"Clin Nucl Med"},{"key":"bib21-20250621","first-page":"150025","article-title":"Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors","volume":"2015","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.3903","article-title":"Nonremission and recurrent tumor-induced osteomalacia: a retrospective study","volume":"35","year":"2020","journal-title":"J Bone Miner Res"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/RLU.0000000000002205","article-title":"Recurrent\/residual intracranial phosphaturic mesenchymal tumor revealed on 68Ga-DOTATATE PET\/CT","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib24-20250621","article-title":"Surgical margin for phosphaturic mesenchymal tumors in soft tissues: an analysis of the radiological histopathological correlation","year":"2020","journal-title":"J Orthop Sci"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jos.2019.02.005","article-title":"Infiltrative nature of tumor-induced osteomalacia lesions in bone: correlation between radiological and histopathological features","volume":"24","year":"2019","journal-title":"J Orthop Sci"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00259-017-3811-4","article-title":"Diagnostic and prognostic value of 18F-FDG PET\/CT in recurrent germinal tumor carcinoma","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1097\/RLU.0000000000002531","article-title":"The prognostic value of baseline 18F-FDG PET\/CT in human papillomavirus\u2013positive versus human papillomavirus\u2013negative patients with oropharyngeal cancer","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/RLU.0000000000002732","article-title":"Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with Hodgkin lymphoma","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/RLU.0000000000002927","article-title":"Prognostic value of 18F-FDG PET\/CT-metabolic parameters at baseline and interim assessment in Pediatric anaplastic large cell lymphoma","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic value of baseline total metabolic tumor volume measured on FDG PET in patients with Richter syndrome","volume":"45","year":"2020","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:04:03Z","timestamp":1750539843000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003463","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,22]]}}}